Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis

Banerjee, Subham; Roy, Subhadeep; Bhaumik, Kaushik Nath; Pillai, Jonathan

doi:10.1080/1061186x.2019.1613409

Cited by 44 publications

(17 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have not followed any conjugation chemistry, which is related to the conjugation of SC with siRNA, as our intention was not to make a lipid-antibody conjugate (by any covalent bond formation). We have rather been much more focused on the preparation of simple solid lipid nanoparticles using a modified multiple emulsification technique using an aqueous template as previously reported [29]. The Vegfr3 antibody ensured that the molecule was specifically taken up by the LSECs and not other cells, as clearly observed in the in vivo localization studies.…”

Section: Discussionmentioning

confidence: 98%

Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH

Tripathi

Rohilla

Kaur

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Background: Runt-related transcription factor (RUNX1) regulates inflammation in non-alcoholic steatohepatitis (NASH). Methods: We performed in vivo targeted silencing of the RUNX1 gene in liver sinusoidal endothelial cells (LSECs) by using vegfr3 antibody tagged immunonano-lipocarriers encapsulated RUNX1 siRNA (RUNX1 siRNA) in murine models of methionine choline deficient (MCD) diet-induced NASH. MCD mice given nanolipocarriers-encapsulated negative siRNA were vehicle, and mice with standard diet were controls. Results: Liver RUNX1 expression was increased in the LSECs of MCD mice in comparison to controls. RUNX1 protein expression was decreased by 40% in CD31-positive LSECs of RUNX1 siRNA mice in comparison to vehicle, resulting in the downregulation of adhesion molecules, ICAM1 expression, and VCAM1 expression in LSECs. There was a marked decrease in infiltrated T cells and myeloid cells along with reduced inflammatory cytokines in the liver of RUNX1 siRNA mice as compared to that observed in the vehicle. Conclusions: In vivo LSEC-specific silencing of RUNX1 using immunonano-lipocarriers encapsulated siRNA effectively reduces its expression of adhesion molecules, infiltrate on of immune cells in liver, and inflammation in NASH.

show abstract

Section: Discussionmentioning

confidence: 98%

Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH

Tripathi

Rohilla

Kaur

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…A549 cells were employed for the evaluation of toxicity, which depicted no significant cytotoxicity. A sustained release of 37% was reported from SLN, while the free drug has a release of 43% The in vivo studies revealed that the relative BA from the SLN was 7.5 fold higher than the drug suspension, proving the effectiveness of the developed formulation [49].…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 90%

Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention

Nabi

Rehman

Aggarwal

et al. 2020

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Tuberculosis (TB) classified as one of the most fatal contagious diseases is of prime concern globally. Mycobacterium tuberculosis is the causative agent that ingresses within the host cells. The approved conventional regimen, though the only viable option available, is unfavorably impacting the quality of life of the affected individual. Despite newer antibiotics gaining light, there is an unending demand for more therapeutic alternatives. Therefore, substantial continuous endeavors are been undertaken to come up with novel strategies to curb the disease, the stepping stone being nanotechnology. This approach is instrumental in overcoming the anomalies associated with conventional therapy owing to their intriguing attributes and leads to optimization of the therapeutic effect to a certain extent. This review focusses on the different types of nanocarrier systems that are being currently explored by the researchers for the delivery of anti-tubercular drugs, the outcomes achieved by them, and their prospects.

show abstract

“…Antimalarial, antifertility activity of curcumin and andrographolide have shown a synergistic effect [16][17][18]. To overcome the bioavailability constraints of these drugs, we have incorporated andrographolide and curcumin into a nanostructured lipid carrier (NLC) system [19]. It has been demonstrated that the therapeutic activity of a drug can be correlated to its drug loading values [20].…”

Section: Fig 2: Chemical Structure Of Curcuminmentioning

confidence: 99%

Analytical Method Development, Validation and Stability Studies by Rp-HPLC Method for Simultaneous Estimation of Andrographolide and Curcumin in Co-Encapsulated Nanostructured Lipid Carrier Drug Delivery System

Bera

2021

Int J App Pharm

View full text Add to dashboard Cite

Objective: The current study aims to boost the bioavailability criteria of two natural bioactive compounds, andrographolide and curcumin by their combination in nanostructured lipid carrier (NLC) and also to develop a straightforward reverse-phase high-performance liquid chromatography (RP-HPLC) method to validate, quantify of andrographolide and curcumin simultaneously in novel NLC formulation. Methods: The reliable chromatographic separation was executed by using a column of Phenomenex octadecylsilane (C18) at 35 °C column oven temperature using a mobile phase of 0.02 M potassium dihydrogen orthophosphate (KH2PO4) salt solution of pH 3.0 as a buffer and acetonitrile in 50: 50 v/v fixed ratio and 1.5 ml/min flow rate of with 20 μl injection load. The detection was carried out at 240 nm isosbestic wavelength employing a photodiode array (PDA) detector. Results: Andrographolide and curcumin were eluted at 2.4 and 4.9 min, respectively. Quantification and linearity were achieved for both drugs at the 10-140 μg/ml range. The method is specified as the presence of excipients utilized in the formulation failed to interfere with the estimation of andrographolide and curcumin. The developed method was successfully utilized to work out the drug loading efficiency and in vitro drug release study of those drugs in NLC formulation and also for the estimation of those drugs from rat plasma. Conclusion: The developed high-performance liquid chromatography (HPLC) method may be utilized in the future estimation of andrographolide and curcumin simultaneously in NLC and other nanoformulations both in vitro and in vivo.

show abstract

Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis

Cited by 44 publications

References 60 publications

Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH

Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH

Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention

Analytical Method Development, Validation and Stability Studies by Rp-HPLC Method for Simultaneous Estimation of Andrographolide and Curcumin in Co-Encapsulated Nanostructured Lipid Carrier Drug Delivery System

Contact Info

Product

Resources

About